What is Quest Diagnostics's market cap?

Quest Diagnostics (DGX) has a market capitalization of $23.0B and trades on NYSE.

What is Quest Diagnostics's revenue and profitability?

Quest Diagnostics generated $11.3B in trailing twelve-month revenue with net income of $1.0B, representing a net margin of 9.1%. Gross margin stands at 33.2%, with free cash flow of $1.3B. These figures are based on the Q1 2026 filing.

Who are Quest Diagnostics's competitors?

Quest Diagnostics's key competitors include Laboratory Corporation of America Holdings, Bio-Rad Laboratories, Inc.Class A, Personalis, Inc. Common Stock, and others. These companies compete in similar markets and product categories.

Who does Quest Diagnostics partner with?

Quest Diagnostics's notable partners include Google, Epic, UnitedHealthcare, and others.

What subsidiaries does Quest Diagnostics have?

Quest Diagnostics's subsidiaries include LifeLabs, Haystack Oncology, Spectra Laboratories, and others.

Where is Quest Diagnostics headquartered?

Quest Diagnostics is headquartered in United States of America and employs approximately 48,000 people. It has been publicly traded since 1996.

Quest Diagnostics

DGX

Quest Diagnostics is a leading provider of diagnostic information services, offering a comprehensive menu of laboratory testing and clinical insights to empower healthcare decisions.

Market cap

$23.05B+16.7%

Revenue$11.3B+11.0%

Net income$1.0B+14.2%

Free cash flow$1.3B+25.6%

EPS (diluted)$9.05+14.4%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

April 21, 2026

Revenue$2.9BBeat by $66.5M EPS$2.50Beat by $0.13

Read the full report

Next report

Jul 23, 2026 (In 1 week)

Revenue estimate$3.0B

EPS estimate$2.81

Financials

Q1 2026

Income statement

See full

Revenue$2.9B+9.2%

Gross profit$942.0M+9.2%

Operating income$399.0M+15.3%

Net income$252.0M+14.5%

EPS (diluted)$2.24+15.5%

Balance sheet

See full

Cash & equivalents$393.0M+109%

Total debt$6.4B-2.5%

Total equity$7.4B+6.3%

Total assets$16.7B+5.5%

Cash flow

See full

Operating cash flow$278.0M-11.5%

CapEx$114.0M-2.6%

Free cash flow$164.0M-16.8%

Valuation & ratios

Valuation

See full

Market cap$23.51B+16.7%

Enterprise value$29.52B+12.6%

P/E23×+1.8×

P/S2.1×+0.2×

Profitability

See full

Gross margin33.2%+0.4pp

Operating margin14.3%+0.6pp

Net margin9.1%+0.2pp

FCF margin11.8%+1.4pp

Returns & leverage

See full

Return on equity14.3%+0.9pp

Debt / equity0.9×-0.1×

Current ratio1.2×-0.3×

Segments

By segment

See full

DIS business$2.8B+9.4%

All other operating segments$63.0M0.0%

Competitors

By market cap

Agilent Technologies$37.0B+8.1%

Quest Diagnostics$23.5B+19.2%

Labcorp Holdings$23.3B+7.0%

Bio-Rad Laboratories$7.8B+14.8%

Personalis, Inc.$1.5B+121%

QuidelOrtho Corporation$1.2B-43.2%

Fulgent Genetics, Inc.$597.0M-2.4%

ONC

Onconetix, Inc.$3.9M+56.1%

By revenue growth

Quest Diagnostics+11.0%

Fulgent Genetics, Inc.+9.5%

Agilent Technologies+9.1%

Labcorp Holdings+7.3%

Bio-Rad Laboratories+1.9%

QuidelOrtho Corporation-3.9%

Personalis, Inc.-24.7%

By net margin

Agilent Technologies19.55%+2.0pp

Quest Diagnostics9.08%+0.2pp

Labcorp Holdings6.66%+1.1pp

Bio-Rad Laboratories6.52%+91.7pp

Fulgent Genetics, Inc.-23.04%-9.1pp

QuidelOrtho Corporation-45.57%-32.6pp

Personalis, Inc.-148.11%-50.0pp

Profile

Quest Diagnostics is a leading provider of diagnostic information services, offering a comprehensive menu of laboratory testing and clinical insights to empower healthcare decisions. The company leverages one of the world's largest databases of clinical lab results to serve approximately half of the physicians and hospitals in the United States. Its core value proposition centers on improving health outcomes through innovative, convenient, and affordable diagnostic services across the healthcare ecosystem.

Competitive position

A leading national provider of diagnostic information services with significant scale, serving approximately one-third of the U.S. adult population annually.

GeographiesUnited States, Canada, Puerto Rico

Customer segmentsHealthcare Providers, Insurance Carriers, Enterprise Employers, Individual Consumers

Business modelFee-for-service, Capitation, Direct-to-consumer, B2B Service

SuppliersLaboratory equipment manufacturers, Reagent and chemical suppliers, IT infrastructure and software licensors, Logistics and fuel providers

CustomersPhysicians and specialists, Hospital systems, Health insurance plans, Government healthcare programs (Medicare/Medicaid), Direct-to-consumer patients, Life insurance underwriters

CountryUnited States of America

Listed1996

Employees48.0K

CEOJames E. Davis

SectorHealthcare

IndustryMedical - Diagnostics & Research

Websitequestdiagnostics.com

FilingsSEC EDGAR

Ask your AI about Quest Diagnostics.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Quest Diagnostics's market cap?: Quest Diagnostics (DGX) has a market capitalization of $23.0B and trades on NYSE.
What is Quest Diagnostics's revenue and profitability?: Quest Diagnostics generated $11.3B in trailing twelve-month revenue with net income of $1.0B, representing a net margin of 9.1%. Gross margin stands at 33.2%, with free cash flow of $1.3B. These figures are based on the Q1 2026 filing.
Who are Quest Diagnostics's competitors?: Quest Diagnostics's key competitors include Laboratory Corporation of America Holdings, Bio-Rad Laboratories, Inc.Class A, Personalis, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
Who does Quest Diagnostics partner with?: Quest Diagnostics's notable partners include Google, Epic, UnitedHealthcare, and others.
What subsidiaries does Quest Diagnostics have?: Quest Diagnostics's subsidiaries include LifeLabs, Haystack Oncology, Spectra Laboratories, and others.
Where is Quest Diagnostics headquartered?: Quest Diagnostics is headquartered in United States of America and employs approximately 48,000 people. It has been publicly traded since 1996.